Clinical Trial

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) with brain metastases. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Taletrectinib will be administered according to clinical practice and data on treatment patterns, clinical outcomes, and safety will be collected during routine evaluations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-04.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT07008287
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 100 participants
Start Date 2025-06-04
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-22